Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Context Therapeutics Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors. Form 8-K reports include Regulation FD corporate presentations, operating and financial results, clinical-trial updates, and the FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer.
Proxy and governance filings describe annual meeting matters, director elections, stockholder voting procedures and common stock matters. Charter-related material-event reports document corrections to certificate provisions governing director terms and removal rights, along with associated Delaware court and stockholder-governance disclosures.
Context Therapeutics Inc. Schedule 13G/A discloses that Great Point Partners, LLC and two principals, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, report shared beneficial ownership of 4,683,711 shares of Context Therapeutics common stock, representing 5.22% of the outstanding class based on 89,704,194 shares outstanding. The filing states Great Point is investment manager to two record holders (BVF and BOVF) whose holdings are included in the aggregate, while the reporting parties disclaim beneficial ownership except to the extent of pecuniary interests. The report is filed jointly under a dated joint filing agreement and affirms the holdings were not acquired to influence control.
Avidity Partners and affiliated funds filed a Schedule 13G reporting significant passive holdings in Context Therapeutics Inc. The filing discloses that certain Avidity reporting persons hold shared voting and shared dispositive power over 9,126,176 shares, representing approximately 9.9% of the outstanding common stock. Individual fund positions reported in the filing include Avidity Master Fund LP with 5,183,700 shares (5.6%) and Avidity Private Master Fund I LP with 7,776,296 shares (8.4%). Michael Gregory is listed among the reporting persons with the same shared power totaling 9,126,176 shares.
The filing indicates no sole voting or dispositive power for any reporting person and includes a certification that the securities were not acquired to change or influence control of the issuer. Exhibits referenced in the filing include a Joint Filing Agreement and Control Person Identification.